8-K: Aflac Reports Strong Fourth Quarter Earnings, Boosts Dividend by 16%

Aflac Incorporated announced strong fourth quarter results, with net earnings of $1.9 billion and an 18.2% increase in adjusted earnings, while also reiterating a 16% increase in the first quarter dividend.

Summary

• Aflac Incorporated reported fourth quarter net earnings of $1.9 billion, or $3.42 per diluted share, compared to $268 million, or $0.46 per diluted share, in the same quarter of the previous year.
• Total revenues for the fourth quarter were $5.4 billion, up from $3.8 billion in the fourth quarter of 2023.
• Adjusted earnings for the fourth quarter increased by 18.2% to $865 million, with adjusted earnings per diluted share rising by 24.8% to $1.56.
• For the full year, net earnings were $5.4 billion, or $9.63 per diluted share, compared to $4.7 billion, or $7.78 per diluted share, in 2023.
• Full-year adjusted earnings reached $4.1 billion, or $7.21 per diluted share, compared to $3.7 billion, or $6.23 per diluted share, in the previous year.
• Aflac Japan's net earned premiums decreased by 5.4% in yen terms for the quarter, while pretax adjusted earnings increased by 1.0% in yen.
• Aflac U.S.'s net earned premiums increased by 2.7% in the fourth quarter, and pretax adjusted earnings rose by 9.3%.
• The board of directors declared a first quarter dividend of $0.58 per share, representing a 16% increase.
• The company repurchased $750 million of its common shares in the fourth quarter, with 47.3 million shares remaining authorized for repurchase at the end of December 2024.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results, dividend increase, and strategic growth initiatives. While there are some challenges, the overall tone is optimistic and confident.

Positives

• Aflac's net earnings significantly increased in the fourth quarter, reaching $1.9 billion.
• Adjusted earnings per diluted share showed a strong increase of 24.8%.
• The company demonstrated its commitment to shareholders by increasing the dividend by 16%.
• Aflac Japan's pretax adjusted profit margin improved to 31.6%.
• Aflac U.S. experienced growth in net earned premiums and pretax adjusted earnings.
• The company actively managed its capital, repurchasing $750 million in shares.
• Persistency in Aflac Japan remained solid at 93.4%.
• Persistency in Aflac U.S. increased 70 basis points year over year to 79.3%.

Negatives

• Aflac Japan's net earned premiums decreased by 5.4% in yen terms for the quarter, mainly due to internal cancer reinsurance transactions and limited-pay policies reaching paid-up status.
• Aflac U.S. sales decreased 4.5% in the quarter, reflecting lower sales of group voluntary benefit products and softer sales of network dental.
• The weaker yen/dollar exchange rate negatively impacted adjusted earnings per share by $0.01.
• Total new annualized premium sales (sales) increased 9.0% to 17.2 billion, or $113 million, primarily reflecting strong sales of Tsumitasu, the new first sector product.

Risks

• The company faces risks related to difficult conditions in global capital markets and the economy, including inflation.
• Fluctuations in interest rates and foreign currency exchange rates could impact financial results.
• The company's concentration of business in Japan poses a risk.
• The company faces risks related to defaults and credit downgrades of investments.
• The company faces risks related to the ability to attract and retain qualified sales associates, brokers, employees, and distribution partners.
• The company faces risks related to catastrophic events, including, but not limited to, as a result of climate change, epidemics, pandemics, tornadoes, hurricanes, earthquakes, tsunamis, war or other military action, major public health issues, terrorism or other acts of violence, and damage incidental to such events.

Future Outlook

For 2025, Aflac expects the benefit ratio in Japan to be toward the higher end of the 64% to 66% range and the expense ratio to be on the lower end of the 20% to 23% range, resulting in a pretax profit margin at the lower end of the 30% to 33% range; in the U.S., the benefit ratio is expected to be at the lower end of the 48% to 52% range and the expense ratio at the upper end of the 36% to 39% range, with a pretax profit margin at the upper end of the 17% to 20% range.

Management Comments

• 'I am pleased that Aflac delivered very solid adjusted earnings for the quarter and the year,' stated Aflac Incorporated Chairman and Chief Executive Officer Daniel P. Amos.
• He added, 'We have continued to actively concentrate on generating profitable growth in the U.S. and Japan with new products and distribution strategies. We believe our strategy will continue to create long-term value for shareholders.'

Industry Context

Aflac's focus on supplemental health insurance products in the U.S. and cancer and medical insurance in Japan positions it well within its respective markets, as it maintains leading positions in both.

Comparison to Industry Standards

• Aflac's annualized return on average shareholders equity in the fourth quarter was 29.9%, which is a strong result compared to the industry average.
• Aflac's persistency rates in Japan (93.4%) and the U.S. (79.3%) are competitive within the insurance industry.
• Aflac's capital ratios, including an SMR above 1,150% and an estimated ESR above 270%, indicate a strong capital position compared to industry peers.
• Comparable companies in the supplemental insurance space include Unum Group, Cigna, and MetLife, which also focus on providing financial protection and peace of mind to policyholders.

Stakeholder Impact

• Shareholders will benefit from the increased dividend and share repurchase program.
• Policyholders will continue to receive financial protection and peace of mind through Aflac's insurance products.
• Employees will be part of a company that is focused on growth and long-term value creation.

Next Steps

• Aflac Incorporated will webcast its quarterly conference call via the Investors page of aflac.com at 8:00 a.m. (ET) on February 6, 2025.
• The company intends to continue its balanced approach of investing in growth and driving long-term operating efficiencies.

Key Dates